Richard Douglas - Net Worth and Insider Trading
Richard Douglas Net Worth
The estimated net worth of Richard Douglas is at least $1 Million dollars as of 2024-12-15. Richard Douglas is the Director of Aldeyra Therapeutics Inc and owns about 125,000 shares of Aldeyra Therapeutics Inc (ALDX) stock worth over $612,500. Richard Douglas is the Director of MaxCyte Inc and owns about 100,000 shares of MaxCyte Inc (MXCT) stock worth over $428,000. Richard Douglas is also the Director of Novavax Inc and owns about 27,500 shares of Novavax Inc (NVAX) stock worth over $250,525. Details can be seen in Richard Douglas's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Richard Douglas has not made any transactions after 2023-03-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Richard Douglas
Richard Douglas Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Richard Douglas owns 3 companies in total, including Novavax Inc (NVAX) , Aldeyra Therapeutics Inc (ALDX) , and MaxCyte Inc (MXCT) .
Click here to see the complete history of Richard Douglas’s form 4 insider trades.
Insider Ownership Summary of Richard Douglas
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NVAX | Novavax Inc | 2017-05-11 | director |
| ALDX | Aldeyra Therapeutics Inc | 2020-03-16 | director |
| MXCT | MaxCyte Inc | 2023-03-29 | director |
Richard Douglas Latest Holdings Summary
Richard Douglas currently owns a total of 3 stocks. Among these stocks, Richard Douglas owns 125,000 shares of Aldeyra Therapeutics Inc (ALDX) as of March 16, 2020, with a value of $612,500 and a weighting of 47.44%. Richard Douglas owns 100,000 shares of MaxCyte Inc (MXCT) as of March 29, 2023, with a value of $428,000 and a weighting of 33.15%. Richard Douglas also owns 27,500 shares of Novavax Inc (NVAX) as of May 11, 2017, with a value of $250,525 and a weighting of 19.41%.
Latest Holdings of Richard Douglas
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALDX | Aldeyra Therapeutics Inc | 2020-03-16 | 125,000 | 4.90 | 612,500 |
| MXCT | MaxCyte Inc | 2023-03-29 | 100,000 | 4.28 | 428,000 |
| NVAX | Novavax Inc | 2017-05-11 | 27,500 | 9.11 | 250,525 |
Holding Weightings of Richard Douglas
Richard Douglas Form 4 Trading Tracker
According to the SEC Form 4 filings, Richard Douglas has made a total of 1 transactions in Aldeyra Therapeutics Inc (ALDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aldeyra Therapeutics Inc is the acquisition of 40,000 shares on March 16, 2020, which cost Richard Douglas around $110,000.
According to the SEC Form 4 filings, Richard Douglas has made a total of 2 transactions in MaxCyte Inc (MXCT) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in MaxCyte Inc is the acquisition of 80,000 shares on March 29, 2023, which cost Richard Douglas around $345,600.
According to the SEC Form 4 filings, Richard Douglas has made a total of 0 transactions in Novavax Inc (NVAX) over the past 5 years. The most-recent trade in Novavax Inc is the acquisition of 10,000 shares on May 11, 2017, which cost Richard Douglas around $186,000.
Insider Trading History of Richard Douglas
- 1
Richard Douglas Trading Performance
GuruFocus tracks the stock performance after each of Richard Douglas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Richard Douglas is 16.71%. GuruFocus also compares Richard Douglas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Richard Douglas within 3 months outperforms 6 times out of 14 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Richard Douglas's insider trading performs compared to the benchmark.
Performance of Richard Douglas
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 9.56 | | | | | |
| Relative Return to S&P 500(%) | 7.76 | | | | | |
Richard Douglas Ownership Network
Ownership Network List of Richard Douglas
Ownership Network Relation of Richard Douglas
Richard Douglas Owned Company Details
What does Novavax Inc do?
Who are the key executives at Novavax Inc?
Richard Douglas is the director of Novavax Inc. Other key executives at Novavax Inc include President & R&D Filip Dubovsky , President & R&D Gregory M Glenn , and EVP & Chief Strategy Officer Elaine O'hara .
Novavax Inc (NVAX) Insider Trades Summary
Over the past 18 months, Richard Douglas made no insider transaction in Novavax Inc (NVAX). Other recent insider transactions involving Novavax Inc (NVAX) include a net sale of 61,216 shares made by Filip Dubovsky , and a net sale of 15,000 shares made by James F Young .
In summary, during the past 3 months, insiders sold 0 shares of Novavax Inc (NVAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 76,216 shares of Novavax Inc (NVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 76,216 shares.
Novavax Inc (NVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Novavax Inc Insider Transactions
Richard Douglas Mailing Address
Above is the net worth, insider trading, and ownership report for Richard Douglas. You might contact Richard Douglas via mailing address: One Kendall Square, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
